Occl Ltd vs Tatva Chintan Pharma Chem Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Mar 18, 2026

Key Highlights

The Latest Trading Price of OCCL Ltd is ₹ 88.09 as of 18 Mar 15:30 . The P/E Ratio of OCCL Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Tatva Chintan Pharma Chem Ltd changed from 53.4 on March 2022 to 278.3 on March 2025 . This represents a CAGR of 51.09% over 4 years The Market Cap of OCCL Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Tatva Chintan Pharma Chem Ltd changed from ₹ 5115 crore on March 2022 to ₹ 1588 crore on March 2025 . This represents a CAGR of -25.35% over 4 years The revenue of OCCL Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Tatva Chintan Pharma Chem Ltd for the Dec '25 is ₹ 133.07 crore as compare to the Sep '25 revenue of ₹ 124.52 crore. This represent the growth of 6.87% The ebitda of OCCL Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Tatva Chintan Pharma Chem Ltd for the Dec '25 is ₹ 27.22 crore as compare to the Sep '25 ebitda of ₹ 23.22 crore. This represent the growth of 17.23% The net profit of OCCL Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Tatva Chintan Pharma Chem Ltd changed from ₹ 5.21 crore to ₹ 15.17 crore over 7 quarters. This represents a CAGR of 84.17% The Dividend Payout of OCCL Ltd changed from 34.98 % on March 2025 to 34.98 % on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe Dividend Payout of Tatva Chintan Pharma Chem Ltd changed from 19.56 % on March 2021 to 708.79 % on March 2025 . This represents a CAGR of 105.04% over 5 years .

About OCCL Ltd

OCCL Limited was incorporated on April 25, 2022, at Mundra, Kachchh, Gujarat with a Certificate of Incorporation issued by the RoC. The Company belongs to the AG Ventures Group of companies.
The Company's first insoluble sulphur manufacturing facility, (transferred from demerged entity), was set up in 1994 in Dharuhera to manufacture insoluble sulphur, now its flagship product. The Company manufactures commercial grade and battery grade sulphuric acid and oleum at its Dharuhera Plant.
The Company's state-of-the-art manufacturing facilities are located in Dharuhera in Haryana and Mundra in Gujarat. The Company commenced production of Sulphuric Acid in 1978; commenced production capacity of 3,000 MT per annum Insoluble Sulphur in 1994; established a second line of business at Dharuhera in 2005; commenced construction of plant at Mundra in 2009; commissioned the first line of 5500 MTPA at Mundra Plant in 2011; commissioned the second line of insoluble sulphur at Mundra with production capacity of 5500 MTPA in 2012; expanded the additional 11,000 TPA of insoluble sulphur capacity at Mundra in 2016; commissioned the third line of insoluble sulphur with installed capacity of 5500 MTPA at Mundra Plant in 2017; commissioned the fourth line of insoluble sulphur with 5500 MTPA at Mundra in 2018; commissioned the expansion of 5500 MTPA insoluble sulphur at Dharuhera Plant in 2021; commissioned an additional 42000 MTPA capacity of sulphuric acid at Dharuhera Plant in 2022.

About Tatva Chintan Pharma Chem Ltd

Tatva Chintan Pharma Chem Limited was formerly incorporated as 'Tatva Chintan Pharma Chem Private Limited' on 12 June 1996.
The status of the Company converted from Private Limited into a Public Limited Company from 27 January 2021 and the name of Company changed from 'Tatva Chintan Pharma Chem Private Limited' to 'Tatva Chintan Pharma Chem Limited'.
The Company is promoted by Mr. Chintan Nitin Kumar Shah, Mr. Ajay Kumar Mansukhlal Patel and Mr. Shekhar Rasiklal Somani. The Company is a globally recognized specialty chemical player with several market leading products in its portfolio.
The Company is primarily engaged in manufacturing, distribution and selling of specialty chemicals i.e., Phase Transfer Catalysts (PTC), Structure Directing Agents (SDA), Electrolyte Salts and Solutions (ESS), Pharmaceutical and Agrochemical Intermediates and Other Specialty Chemicals (PASC).

FAQs for the comparison of OCCL Ltd and Tatva Chintan Pharma Chem Ltd

Which company has a larger market capitalization, OCCL Ltd or Tatva Chintan Pharma Chem Ltd?

Market cap of OCCL Ltd is 440 Cr while Market cap of Tatva Chintan Pharma Chem Ltd is 2,766 Cr

What are the key factors driving the stock performance of OCCL Ltd and Tatva Chintan Pharma Chem Ltd?

The stock performance of OCCL Ltd and Tatva Chintan Pharma Chem Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for OCCL Ltd and Tatva Chintan Pharma Chem Ltd?

As of March 18, 2026, the OCCL Ltd stock price is INR ₹88.09. On the other hand, Tatva Chintan Pharma Chem Ltd stock price is INR ₹1182.85.

How do dividend payouts of OCCL Ltd and Tatva Chintan Pharma Chem Ltd compare?

To compare the dividend payouts of OCCL Ltd and Tatva Chintan Pharma Chem Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.